- Home
- ARVN vs BLW Comparison
ARVN vs BLW Comparison
Compare ARVN & BLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARVN | BLW |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 498.3M |
| IPO Year | 2018 | 2003 |
Fundamental Metrics
Financial Performance| Metric | ARVN | BLW |
|---|---|---|
| Price | $6.79 | $11.47 |
| Analyst Decision | Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 859.5K | 182.1K |
| Earning Date | 11-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | $5.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.33 | $11.35 |
| 52 Week High | $14.22 | $14.00 |
Technical Indicators
Market Signals| Indicator | ARVN | BLW |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 42.31 |
| Support Level | $6.74 | $11.43 |
| Resistance Level | $7.85 | $11.94 |
| Average True Range (ATR) | 0.47 | 0.17 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 27.06 | 21.96 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
About BLW Blackrock Limited Duration Income Trust
Blackrock Ltd Duration Income Trust is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation.